Pulse Biosciences Inc (PLSE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Pulse Biosciences Inc (PLSE) has a cash flow conversion efficiency ratio of -0.188x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-18.71 Million) by net assets ($99.50 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see market value of Pulse Biosciences Inc for the company's overall valuation and market capitalisation.
Pulse Biosciences Inc - Cash Flow Conversion Efficiency Trend (2014–2025)
This chart illustrates how Pulse Biosciences Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Pulse Biosciences Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Pulse Biosciences Inc ranked by their cash flow conversion efficiency. See PLSE cash flow to debt ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Jiangsu Phoenix Publishing & Media Corp Ltd
SHG:601928
|
0.031x |
|
Concentra Group Holdings Parent, Inc.
NYSE:CON
|
0.046x |
|
Veracyte Inc
NASDAQ:VCYT
|
0.033x |
|
Nuode Investment Co Ltd
SHG:600110
|
0.013x |
|
SF Diamond
SHE:300179
|
-0.023x |
|
Shenzhen InfoGem Technologies Co Ltd
SHE:300085
|
0.129x |
|
Madison Square Garden Entertainment Corp
NYSE:MSGE
|
0.082x |
|
FangDa Carbon New Material Co Ltd
SHG:600516
|
-0.012x |
Annual Cash Flow Conversion Efficiency for Pulse Biosciences Inc (2014–2025)
The table below shows the annual cash flow conversion efficiency of Pulse Biosciences Inc from 2014 to 2025. View current stock price of Pulse Biosciences Inc for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $80.66 Million | $-54.12 Million | -0.671x | -112.08% |
| 2024-12-31 | $114.86 Million | $-36.34 Million | -0.316x | +57.52% |
| 2023-12-31 | $44.36 Million | $-33.04 Million | -0.745x | -103.56% |
| 2022-12-31 | $-2.25 Million | $-47.01 Million | 20.913x | +1479.73% |
| 2021-12-31 | $35.69 Million | $-54.10 Million | -1.516x | +1.88% |
| 2020-12-31 | $22.89 Million | $-35.37 Million | -1.545x | -38.89% |
| 2019-12-31 | $30.74 Million | $-34.19 Million | -1.112x | -208.73% |
| 2018-12-31 | $66.33 Million | $-23.90 Million | -0.360x | -49.45% |
| 2017-12-31 | $45.99 Million | $-11.09 Million | -0.241x | +24.26% |
| 2016-12-31 | $25.30 Million | $-8.05 Million | -0.318x | -31.12% |
| 2015-12-31 | $13.67 Million | $-3.32 Million | -0.243x | -2153.35% |
| 2014-12-31 | $16.07 Million | $-173.14K | -0.011x | -- |
About Pulse Biosciences Inc
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers nPulse System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; nPulse Vybrance Percutaneous Electrode system for soft tissue ablation in surgical setting; nPulse Cardiac Surgical Clamp designed for use in surgical treatment of atrial fibrillation (AF); nPulse Cardiac… Read more